Related Experiment Video
Updated: Aug 27, 2025
10:32
Transcriptomic Analysis of Human Retinal Surgical Specimens Using jouRNAl
Published on: August 14, 2013
7.9K
Long non-coding RNAs in retinal neovascularization: current research and future directions
Wenye Cao1, Ningzhi Zhang1, Xuejun He1
1Department of Ophthalmology, Renmin Hospital of Wuhan University, Jiefang Road #238, Wuhan, 430060, Hubei, China.
Summary
Long non-coding RNAs (lncRNAs) are key regulators of retinal neovascularization (RNV). While MEG3 attenuates RNV, MALAT1, MIAT, ANRIL, HOTAIR, HOTTIP, and SNHG16 promote it, offering potential therapeutic targets for blinding eye diseases.
Area of Science:
- Ophthalmology
- Molecular Biology
- Genetics
Background:
- Retinal neovascularization (RNV) is a major cause of blindness in diseases like diabetic retinopathy.
- Current treatments for RNV have limitations and side effects.
- Understanding RNV pathogenesis and identifying new therapeutic targets are crucial.
Purpose of the Study:
- To review the expression and regulatory roles of long non-coding RNAs (lncRNAs) in pathological RNV.
- To highlight lncRNAs as potential therapeutic targets for RNV-related diseases.
Main Methods:
- Comprehensive literature search of PubMed and Web of Science databases.
- Review and synthesis of published research on lncRNAs and RNV.
Main Results:
- lncRNA MEG3 demonstrates a protective role by attenuating RNV under high glucose stress.
- lncRNAs MALAT1, MIAT, ANRIL, HOTAIR, HOTTIP, and SNHG16 are implicated in the pathological progression of RNV.
- Specific lncRNAs exhibit opposing roles in RNV development.
Conclusions:
- lncRNAs play significant roles in the pathogenesis of RNV.
- Targeting specific lncRNAs presents a promising therapeutic strategy for RNV and associated blinding conditions.
- Further research into lncRNA functions can lead to novel treatment options.
